WO2008007766A1 - Cristal de dÉrivÉ de benzoxadiazole - Google Patents
Cristal de dÉrivÉ de benzoxadiazoleInfo
- Publication number
- WO2008007766A1 WO2008007766A1 PCT/JP2007/063960 JP2007063960W WO2008007766A1 WO 2008007766 A1 WO2008007766 A1 WO 2008007766A1 JP 2007063960 W JP2007063960 W JP 2007063960W WO 2008007766 A1 WO2008007766 A1 WO 2008007766A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal
- isopropyl
- pyridyl
- pharmaceutical composition
- phenol
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 189
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical class C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 title abstract description 3
- 238000000113 differential scanning calorimetry Methods 0.000 claims abstract description 47
- 239000003814 drug Substances 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 27
- 229940124597 therapeutic agent Drugs 0.000 claims description 19
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 16
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 claims description 13
- 201000000980 schizophrenia Diseases 0.000 claims description 12
- 206010012289 Dementia Diseases 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 11
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 9
- 229940088352 Glycine transporter inhibitor Drugs 0.000 claims description 8
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- FQGLDGKVKDPVLO-UHFFFAOYSA-N 4-[3-(6-phenylpyridin-3-yl)-5-propan-2-yl-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole Chemical compound C=1C=CC2=NON=C2C=1N1C(C(C)C)=NN=C1C(C=N1)=CC=C1C1=CC=CC=C1 FQGLDGKVKDPVLO-UHFFFAOYSA-N 0.000 abstract 1
- 238000002050 diffraction method Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 24
- 238000010586 diagram Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 229940126062 Compound A Drugs 0.000 description 12
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 229940088679 drug related substance Drugs 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 8
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003701 inert diluent Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- -1 6-phenyl-1-pyridyl Chemical group 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 241001055367 Dario Species 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 229910020939 NaC104 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- CHRHZFQUDFAQEQ-UHFFFAOYSA-L calcium;2-hydroxyacetate Chemical compound [Ca+2].OCC([O-])=O.OCC([O-])=O CHRHZFQUDFAQEQ-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N methyl ethyl ketone Substances CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to 4 [3-isopropyl-5- (6-ferro-3-pyridyl) -411 1, 2, 4 triazole-4 yl] 2, 1, 3 benzoxaziazole (hereinafter, It may be simply referred to as “Compound A”). More specifically, a single crystal having a certain quality can be obtained with good reproducibility and can be stably supplied as a crystal of a drug substance used in the manufacture of a pharmaceutical, and is suitable for mass synthesis in industrial production.
- the present invention relates to a pharmaceutical composition useful as an agent or a therapeutic agent for schizophrenia.
- the inventors of the present invention have the following chemical structural formula: 4 [3 isopropyl-5- (6 phenol-3 pyridyl) 4 ⁇ - 1, 2, 4 triazole-4-yl] -2, 1, 3 Benzoxadiazole (I compound) It has been reported that it is useful as a drug, particularly a glycine transporter activity inhibitor, for example, as a therapeutic agent for dementia and schizophrenia (Patent Document 1: See Example 2).
- Example 2 of Patent Document 1 compound ⁇ is converted into 4- [3-isopropyl-5- (6-phenolpyridine-3-yl) 4H-1, 2, 4 triazole-4-yl].
- —2 1, 3 Benzoxaziazole, a force named as 4— [3-Isopropyl 5- (6-Feryl 3-pyridyl) 4H— 1, 2, 4 Triazole 4— Yl] -2,1,3 benzoxaziazole, and all the designations represent the following compounds:
- Patent Document 1 Pamphlet of International Publication No. 2001Z87855
- Example 2 of Patent Document 1 a white crystal of Compound A having a melting point of 107 to 108 ° C is described, but other crystal polymorphs are not described at all.
- the present inventors have found that Compound A has the oc (alpha) form, ⁇ (beta one) form, y (gamma one) form, and ⁇ (delta) form. The presence of a total of four crystal polymorphs was confirmed.
- the white crystal of Compound A described as having a melting point of 107 to 108 ° C. is a ⁇ -type crystal.
- the ⁇ -form crystal of compound ⁇ can be obtained on a small scale, but in the manufacturing process of a drug substance for mass synthesis, a target single crystal It was found that it was technically difficult to obtain this with good reproducibility. In addition, it has been technically difficult to stably supply crystals of a drug substance with a certain quality, and it has been quite difficult to supply them stably. Furthermore, the ⁇ -form crystal has a hygroscopic property and is unstable to light. Therefore, there is a problem that it is practically impossible to use the ⁇ form crystal of Compound A as a drug substance in the manufacture of a medicine.
- the present invention has been made to solve the above-described problems. Specifically, a single crystal having a certain quality can be obtained with good reproducibility, and the drug substance used in the manufacture of a drug can be obtained. It can be stably supplied as crystals and is suitable for mass production in industrial production. It is difficult to show hygroscopicity. Especially, it has excellent photostability, and it has excellent storage stability.
- the object is to provide ⁇ -form crystals, ⁇ -form crystals, and oc-form crystals.
- the present inventors have conducted extensive research on the crystal polymorph of compound ⁇ , and as a result, in the case of ⁇ -form crystal, ⁇ -form crystal, and a-form crystal of Compound A, certain products are obtained.
- Single crystals with high quality can be obtained with good reproducibility, can be stably supplied as crystals of the drug substance used in the manufacture of pharmaceuticals, can avoid hygroscopicity, and have excellent light stability.
- a pharmaceutical composition comprising the crystal form 13 according to any one of [1] to [4] as an active ingredient.
- a pharmaceutical composition comprising the ⁇ -form crystal according to any one of [9] to [12] as an active ingredient.
- a pharmaceutical composition comprising the ⁇ -form crystal according to any one of [17] to [20] as an active ingredient.
- a single crystal having a certain quality can be obtained with good reproducibility, and can be stably supplied as a crystal of a drug substance used in the manufacture of a medicine, thereby avoiding hygroscopicity.
- it is useful as a therapeutic agent for dementia or schizophrenia, which is a novel 13-type crystal, ⁇ -type crystal, and ⁇ -type crystal of compound ⁇ that is particularly excellent in photostability, and contains these as active ingredients.
- a pharmaceutical composition is provided.
- the present invention ⁇ -form crystal 4- [3-Isopropyl-5- (6-phenol-3 pyridyl) -4H-1,2,4 triazole-4-yl] -2,1,3-benzoxaziazole j8 form of the present invention Crystals, ⁇ -form crystals, and ⁇ -form crystals (hereinafter sometimes referred to as “the present invention ⁇ -form crystal”, “the present invention ⁇ -form crystal”, and “the present invention ⁇ -form crystal”) are as described above. Unlike the known ⁇ -type crystal, a single crystal having a certain quality can be obtained with good reproducibility. In addition, these can be stably supplied as crystals of the drug substance used in the manufacture of pharmaceuticals, can avoid hygroscopicity, and are particularly excellent in light stability. These crystal form differences are distinguished in particular by differential scanning calorimetry analysis (DSC analysis) and powder X-ray diffraction.
- DSC analysis differential scanning calorimetry analysis
- powder X-ray diffraction
- the ⁇ -form crystal of the present invention has an endothermic peak at 145 to 150 ° C. by differential scanning calorimetry analysis (DSC analysis), and 2 ⁇ (°) 9. by Z or powder X-ray diffraction. 8, 11. 1, 12. 8, 13 .3, 17.1, 20.2, 21.2, and 22.3.
- the ⁇ -form crystal of the present invention has an endothermic peak at 149 to 154 ° C by differential scanning calorimetry analysis (DSC analysis) and / or 2 ⁇ (°) 8.3, 16 by powder X-ray diffraction. 7, 18. 9, 21.4, 2 2. 2, 23.0, 24.6, 24.9, and 25.6 have peaks.
- the ⁇ -form crystal of the present invention has an endothermic peak at 168 to 173 ° C. by differential scanning calorimetry analysis (DSC analysis) and / or 2 ⁇ (°) 9. 1, 10 by powder X-ray diffraction. .4, 13.0, 13.7, 19.3, 20.8, 22.9, 25.2, and 25.9 have peaks.
- the known ⁇ -form crystal has a broad endothermic peak near 100 ° C by differential scanning calorimetry analysis (DSC analysis), and 2 ⁇ (°) 6.6 by X or powder X-ray diffraction. 8. 0, 12. 7, 1 5. 3, 18. 0, 20. 0, and 23.0.
- Table 1 shows the diffraction angle (20 (°;)) and relative intensity in the powder X-ray diffraction spectrum of the ⁇ -form crystal, ⁇ -form crystal, and (form X-form crystal and known ⁇ -form crystal) of the present invention.
- the four types of crystals are distinguished from each other by the diffraction angle and relative intensity.
- Powder X-ray diffraction is based on the nature of the data, and the overall pattern of the crystal lattice spacing is important in determining the identity of the crystal.
- the relative intensity depends somewhat on the crystal growth direction, particle size, and measurement conditions. Is a variable and should not be interpreted strictly.
- the temperature was measured at 25 ° C., the measurement range was 5 to 95% relative humidity, and the measurement interval was 5% relative humidity.
- the amount of impurities was measured by HPLC using a light stability tester LTL-200D3J-15 so that the accumulated illuminance was 1.2 million lux (temperature: 25 ° C).
- the ⁇ -type crystal of the present invention can be produced from the composite compound described in Example 2 of Patent Document 1 by, for example, the following method.
- the precipitated crystals are filtered, washed with a mixture of ethanol and water, and dried under reduced pressure to give 4— [3-Isopropyl-5- (6-Ferrolu 3-pyridyl) — 4H —1, 2, 4 Triazole- 4 yl] 2, 1, 3 j8-type crystals of benzoxaziazole can be obtained.
- the ⁇ -type crystal of the present invention can be produced, for example, by the following method.
- the ⁇ -form crystal of the present invention can be produced, for example, by the following method.
- the pharmaceutical composition of the present invention contains the above-mentioned ⁇ -form crystal, ⁇ -form crystal, and ⁇ -form crystal of the present invention, or any combination thereof as an active ingredient, and further a pharmaceutical composition. And is useful as an inhibitor of glycine transporter activity. In particular, it is useful as a therapeutic agent for dementia or a therapeutic agent for schizophrenia.
- a pharmaceutical composition containing one or more of the crystals of the present invention as an active ingredient is a tablet, powder, or the like using a carrier or excipient for pharmaceutical preparations or other additives that are commonly used. It is prepared into fine granules, granules, capsules, pills, solutions, injections, suppositories, ointments, patches, etc. and is administered orally or parenterally.
- the clinical dose of the crystals of the present invention for humans is appropriately determined in consideration of the patient's symptoms, body weight, age and sex, etc., but is usually 0.1 to 500 mg orally per day for an adult, parenterally. 0. 01-: LOOmg, administered in one or several divided doses. Since the dosage varies depending on various conditions, it may be less than the above dosage range and may be sufficient.
- solid compositions for oral administration of the crystals of the present invention tablets, powders, granules and the like are used. I can.
- one or more active substance forces at least one inert diluent such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, poly It is mixed with bull pyrrolidone and magnesium aluminate metasilicate.
- the composition comprises additives other than an inert diluent, for example, a lubricant such as magnesium stearate, a disintegrant such as calcium glycolate, a stabilizer such as ratatose, It may contain a solubilizing agent or solubilizing agent such as gnoretamic acid or aspartic acid. If necessary, tablets or pills may be coated with a sugar coating such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, or a film of a gastric or enteric substance.
- a lubricant such as magnesium stearate
- a disintegrant such as calcium glycolate
- a stabilizer such as ratatose
- solubilizing agent or solubilizing agent such as gnoretamic acid or aspartic acid.
- tablets or pills may be coated with a sugar coating such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, or a film of
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, commonly used inert diluents, Examples include purified water and ethyl alcohol.
- This composition may contain solubilizers, solubilizers, wetting agents, suspending agents, sweeteners, flavors, fragrances, preservatives in addition to the inert diluent. Good.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- aqueous solution and suspension diluent include distilled water for injection and physiological saline.
- diluents for non-aqueous solutions and suspensions include, for example, vegetable oils such as propylene glycol, polyethylene glycol and olive oil; alcohols such as ethyl alcohol; polysorbate 80 (trade name).
- Such a composition further comprises an isotonic agent, preservative, wetting agent, emulsifier, dispersant, stabilizer.
- Additives such as (eg, ratatoses), solubilizers or solubilizers may be included. These are sterilized by, for example, filtration through a bacteria-retaining filter, blending with a bactericide or irradiation. These can also be used by preparing a sterile solid composition and dissolving it in sterile water or a sterile solvent for injection before use.
- Fig. 1 shows the differential scanning calorimeter analysis diagram (DSC analysis diagram) of the ⁇ 8 crystal
- Fig. 2 shows the powder X-ray diffraction pattern.
- Fig. 3 shows the differential scanning calorimeter analysis diagram (DSC analysis diagram) of the bowl-shaped crystal
- Fig. 4 shows the powder X-ray diffraction pattern.
- Fig. 7 shows the differential scanning calorimeter analysis diagram (DSC analysis diagram) of the a-form crystal
- Fig. 8 shows the powder X-ray diffraction pattern.
- Example 2 of Patent Document 1 the title ⁇ -form crystal was obtained.
- FIG. 5 shows a differential scanning calorimeter analysis diagram (DSC analysis diagram) of the ⁇ -form crystal
- FIG. 6 shows a powder X-ray diffraction diagram.
- the crystal of the present invention is excellent in storage stability due to its excellent light stability, which is difficult to show hygroscopicity, and as an inhibitor of glycine transporter activity, for example, dementia, schizophrenia, cognition It is useful as a therapeutic agent for spasticity associated with disorder, cognitive impairment associated with various diseases such as Aruno, Imah's disease, Parkinson's disease, Huntington's disease, or diseases such as neurodegenerative disease and cerebrovascular disorder.
- the ⁇ -form crystal and ⁇ -form crystal of the present invention are not hygroscopic, and the a-form crystal is also a known ⁇ -form crystal It has been confirmed by the hygroscopic test shown below that it has no hygroscopicity!
- the hygroscopicity was measured using VTI SGA-100 under the conditions of temperature: 25 ° C, measurement range: relative humidity 5 to 95%, measurement interval: relative humidity 5%.
- FIG. 9 shows a hygroscopic curve of a known ⁇ -type crystal.
- the known ⁇ -type crystals gradually absorb moisture from a relative humidity of about 50%, show a sudden weight increase from a relative humidity of about 80%, and about 2% at a relative humidity of 95%. Retaining moisture, it was a part of it.
- the ⁇ -form crystal and the ⁇ -form crystal of the present invention show almost no hygroscopicity with a change in weight from low humidity to high humidity (see FIGS. 9 and 10: relative humidity 5% To a relative humidity of 95%, the water retention is 0.2% or less for each.)
- the ⁇ -form crystal of the present invention also shows a certain hygroscopicity, it was found that the hygroscopicity was lower than that of the known ⁇ -form crystal (see FIG. 12).
- 8-type crystal, ⁇ -type crystal, and ⁇ -type crystal of the present invention were particularly excellent in light stability, which was confirmed by the light stability test shown below.
- the accumulated illuminance is 1.2 million lux (temperature: 25 ° C).
- the amount of impurities in the stored sample was measured by HPLC.
- Table 2 below shows the amount of increase in impurities after storage of the ⁇ -form crystal, ⁇ -form crystal, a-form crystal and the known ⁇ -form crystal of the present invention.
- the 13-type crystal, the ⁇ -type crystal, and the ⁇ -type crystal of the present invention do not require light shielding, and improve the convenience as a formulation and do not employ a special formulation process such as production under light shielding. There is a great advantage.
- 8 crystal, ⁇ crystal, and ⁇ crystal of the present invention are excellent glycine transporter inhibitors. It has been confirmed by the following pharmacological tests that it has harmful effects.
- Rats expressing the glycine transporter subtype GLYT1 (J. omeza, F. Zafra, L. Olivares, J. Jimenez, C. Aragon, Regulation by pnorool est ers of the glycine transporter (GLYTl ) in glioolastoma cells., Biochim. Biophys. Acta., 1233,41-46, 1995).
- C6 Dario cell culture (American Type Culture Collection) uses DMEM (Dulbecco ⁇ s Modine d Eagle ⁇ s Medium) containing 10% fetal bovine serum and 100 units / ml penicillin 0.1 mg / ml streptomycin sulfate. Incubate in a CO incubator at
- [ 3 H] glycine uptake was performed according to the method of Gomeza et al. (J. Gomeza, F. Zafra, L. Olivares, C. Gi menez, C. Aragon, Biochim. Biophys. Acta., 1233,41-46, 1995) went.
- C6 Dario cell cells were seeded on 96-well plates (Culturplate, PerkinElmer) at a concentration of 2 ⁇ 10 4 cells Z-well and cultured for 2 days, and then [] glycine uptake experiments were performed. Cells were buffered (150 mM NaCl, 5 mM KC1, 1 mM CaCl, 1 mM MgCl, 10 mM Gluco
- crystal 1 is a differential scanning calorimeter analysis diagram (DSC analysis diagram) of (crystal of the present invention).
- FIG.2 4- [3-Isopropyl-5- (6-Phenol-3-pyridyl) 4H— 1, 2, 4 Triazole- 4 yl] 2, 1, 3 Benzoxadiazole j8 form 1 is a powder X-ray diffraction pattern of a crystal (crystal of the present invention).
- FIG.3 4- [3-Isopropyl-5- (6-Phenol-3-pyridyl) 4H— 1, 2, 4 Triazole-4-yl] —2, 1, 3 ⁇ -form crystal of benzoxaziazole 1 is a differential scanning calorimeter analysis diagram (DSC analysis diagram) of (crystal of the present invention).
- FIG.4 4- [3-Isopropyl-5- (6-Phenol-3-pyridyl) 4 ⁇ - 1, 2, 4 Triazol 4-yl] -2, 1, 3 ⁇ form of benzoxaziazole 1 is a powder X-ray diffraction pattern of a crystal (crystal of the present invention).
- FIG.7 4- [3-Isopropyl-5- (6-Phenol-3Pyridyl) 4 ⁇ - 1, 2, 4 Triazole-4 yl] 2, 1, 3 Benzoxadiazole ⁇ -form crystals 1 is a differential scanning calorimeter analysis diagram (DSC analysis diagram) of (crystal of the present invention).
- FIG. 4 is a hygroscopic curve of a crystal (crystal of the present invention).
- FIG. 4 is a hygroscopic curve of a crystal (crystal of the present invention).
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07790741A EP2042498A4 (en) | 2006-07-14 | 2007-07-13 | CRYSTAL OF BENZOXADIAZOLE DERIVATIVE |
US12/307,843 US8278333B2 (en) | 2006-07-14 | 2007-07-13 | Crystals of benzoxadiazole derivative |
CA002657117A CA2657117A1 (en) | 2006-07-14 | 2007-07-13 | Crystals of benzoxadiazole derivative |
JP2008524852A JP5077232B2 (ja) | 2006-07-14 | 2007-07-13 | ベンゾオキサジアゾール誘導体の結晶 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-193855 | 2006-07-14 | ||
JP2006193855 | 2006-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008007766A1 true WO2008007766A1 (fr) | 2008-01-17 |
Family
ID=38923322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/063960 WO2008007766A1 (fr) | 2006-07-14 | 2007-07-13 | Cristal de dÉrivÉ de benzoxadiazole |
Country Status (6)
Country | Link |
---|---|
US (1) | US8278333B2 (ja) |
EP (1) | EP2042498A4 (ja) |
JP (1) | JP5077232B2 (ja) |
CA (1) | CA2657117A1 (ja) |
TW (1) | TW200811160A (ja) |
WO (1) | WO2008007766A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014214156A (ja) * | 2013-04-26 | 2014-11-17 | エバーライトケミカル インダストリアルコーポレイション | モルフィナン誘導体の結晶、その製造方法、およびそれを用いた医薬組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0741495A (ja) * | 1993-05-28 | 1995-02-10 | Nippon Kayaku Co Ltd | 14α−ヒドロキシ−4−アンドロステン−3,6,17−トリオン水和物結晶及びその製造法 |
WO2001087855A1 (fr) | 2000-05-19 | 2001-11-22 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de triazole |
JP2004175788A (ja) * | 2002-09-13 | 2004-06-24 | Mitsubishi Pharma Corp | 2−アミノ−6−(4−メトキシフェニルチオ)−9−[2−(ホスホノメトキシ)エチル]プリンビス(2,2,2−トリフルオロエチル)エステルの結晶 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0626388A3 (en) * | 1993-05-28 | 1996-06-19 | Nippon Kayaku Kk | 14alpha-hydroxy-4-androstene-3,6,17-trione hydrate crystal and process for producing same. |
US20030216385A1 (en) * | 2000-05-19 | 2003-11-20 | Takahiko Tobe | Triazole derivatives |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
-
2007
- 2007-07-05 TW TW096124494A patent/TW200811160A/zh unknown
- 2007-07-13 WO PCT/JP2007/063960 patent/WO2008007766A1/ja active Application Filing
- 2007-07-13 EP EP07790741A patent/EP2042498A4/en not_active Withdrawn
- 2007-07-13 US US12/307,843 patent/US8278333B2/en not_active Expired - Fee Related
- 2007-07-13 CA CA002657117A patent/CA2657117A1/en not_active Abandoned
- 2007-07-13 JP JP2008524852A patent/JP5077232B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0741495A (ja) * | 1993-05-28 | 1995-02-10 | Nippon Kayaku Co Ltd | 14α−ヒドロキシ−4−アンドロステン−3,6,17−トリオン水和物結晶及びその製造法 |
WO2001087855A1 (fr) | 2000-05-19 | 2001-11-22 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de triazole |
JP2004175788A (ja) * | 2002-09-13 | 2004-06-24 | Mitsubishi Pharma Corp | 2−アミノ−6−(4−メトキシフェニルチオ)−9−[2−(ホスホノメトキシ)エチル]プリンビス(2,2,2−トリフルオロエチル)エステルの結晶 |
Non-Patent Citations (3)
Title |
---|
C. GIMENEZ; C. ARAGON, BIOCHIM. BIOPHYS. ACTA, vol. 1233, 1995, pages 41 - 46 |
J. GOMEZA ET AL.: "Regulation by phorbol esters of the glycine transporter (GLYT1) in glioblastoma cells", BIOCHIM. BIOPHYS. ACTA, vol. 1233, 1995, pages 41 - 46 |
See also references of EP2042498A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014214156A (ja) * | 2013-04-26 | 2014-11-17 | エバーライトケミカル インダストリアルコーポレイション | モルフィナン誘導体の結晶、その製造方法、およびそれを用いた医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP2042498A4 (en) | 2011-11-09 |
US20090203741A1 (en) | 2009-08-13 |
EP2042498A1 (en) | 2009-04-01 |
TW200811160A (en) | 2008-03-01 |
JP5077232B2 (ja) | 2012-11-21 |
JPWO2008007766A1 (ja) | 2009-12-10 |
CA2657117A1 (en) | 2008-01-17 |
US8278333B2 (en) | 2012-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018201897B2 (en) | Solid Forms of an Epidermal Growth Factor Kinase Inhibitor | |
AU2018201896B2 (en) | Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor | |
JP2017105816A (ja) | ((1s,2s,4r)−4−{4−[(1s)−2,3−ジヒドロ−1h−インデン−1−イルアミノ]−7h−ピロロ[2,3−d]ピリミジン−7−イル}−2−ヒドロキシシクロペンチル)スルファミン酸メチルの塩酸塩 | |
US8946249B2 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
KR20090107013A (ko) | 티아졸리딘디온 화합물의 결정질 형태 및 이의 제조 방법 | |
EP3430004A1 (en) | Solid state forms of nilotinib salts | |
EP3551617B1 (en) | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists | |
TW202014412A (zh) | 賽度替尼(cerdulatinib)之固體型式 | |
US11236073B2 (en) | ODM-201 crystalline form, preparation method therefor, and pharmaceutical composition thereof | |
EP3981768A1 (en) | Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof | |
KR20140040671A (ko) | 아프레피탄트 l-프롤린 조성물 및 공결정 | |
TW201829423A (zh) | Janus激酶抑制劑之結晶型 | |
WO2008007766A1 (fr) | Cristal de dÉrivÉ de benzoxadiazole | |
US20060194833A1 (en) | Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses | |
KR20190056398A (ko) | 무스카린 아세틸콜린 수용체 작용제의 결정성 다형체 | |
WO2019242646A1 (zh) | 催产素受体抑制剂的晶型及其制备方法 | |
CN116375624A (zh) | 吡咯烷类化合物的盐及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07790741 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008524852 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007790741 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2657117 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12307843 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |